Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-spectrum versus extended-spectrum beta-lactam therapy for Enterobacteriaceae bacteremia
2015-004219-19Phase 3Completed
- Sponsor
- Fundación Pública Andaluza para la Gestión de la Investigación
- Start
- Feb 2016
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ampicillin, trimethoprim + sulfamethoxazole, cefuroxime, amoxicillin + clavulanate, cefotaxime and 8 more in Bacteremia and bacterial disease (2 arms), sponsored by Fundación Pública Andaluza para la Gestión de la Investigación. Primary endpoint: Clinical cure at 14 days. Started Feb 2016; status: completed.
02
Drugs
ampicillintrimethoprim + sulfamethoxazolecefuroximeamoxicillin + clavulanatecefotaxime
03
Conditions
Bacteremiabacterial disease
Beyond the preview
Go deeper on 2015-004219-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004219-19.